The size of the Asia Pacific Superdisintegrants Market is expected to grow 106.14 million by 2026 and USD 69.24 million in 2021, growing at a CAGR of 8.92% during the forecast period.
The market for superdisintegrants in the APAC region is expected to be driven by factors such as the increased use of orally disintegrating tablets, rising acceptance of advanced technologies, increased R&D activity, increased R&D investment, and increased adoption rate of innovative drug delivery system technology, the growing generics market, and the development of novel superdisintegrants for the pharmaceutical sector. The considerable increase in the healthcare sector and the pharmaceutical business in these regions account for the majority of this growth. In addition, low-cost manufacturing, rising per capita income, and weak governmental regulation contribute to the superdisintegrants market's rise in the Asia Pacific region.
Increased healthcare spending and awareness are the key drivers driving market development. Disintegrants provide several advantages, including precision dosage, quick action, improved patient compliance, palatability, cost-effectiveness, simplicity of administration, no danger of airway suffocation while swallowing, and versatility in terms of large and small molecules. Ispaghula, gellan gum, fenugreek seed mucilage, and gum karaya, among others, offer several benefits over synthetic superdisintegrants, including biodegradability, chemical inertness, and non-toxicity. In addition, it may be changed in various ways to create different materials for medication delivery systems that aim to improve safety by forming an accessible dosing system.
The shift in pharmaceutical production to emerging markets and the general expansion of the pharmaceutical market in these markets provide considerable market growth opportunities. When solid dosage forms like capsules or tablets are submerged in liquid, superdisintegrants are added to help them dissolve. Because of this advantage, superdisintegrants are widely utilized in the production of disintegrating oral formulations, driving the rising demand for superdisintegrants in the market. Furthermore, patients' growing preference for orally disintegrating tablet (ODT) products will generate attractive market opportunities. Since synthetic superdisintegrants have been the industry standard for decades, further research into natural superdisintegrants will boost the market's future growth.
During the forecast period, safety and quality issues are likely to restrict the growth of the Asia Pacific Superdisintegrants market to some extent. Maintaining safety and satisfying the quality requirements of regulators, end-users, medication makers, and, most crucially, patients and achieving immediate efficiency and maximum transparency in supply chain operations are all challenges that market manufacturers face.
This research report on the APAC Superdisintegrants Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Application:
By Therapeutic Area:
By Country:
Geographically, China is leading the market while India is in second place. Large populations and rapid medical advancements have assisted the dominance of China in the market. India is expected to grow the fastest due to increasing healthcare spending, rising healthcare infrastructure, and awareness. Growth in the Asia Pacific area is projected to be driven by increased outsourcing of excipients, including superdisintegrants, production of new superdisintegrants, and the widespread usage of sodium starch glycolate orally fast integrating tablets, and adoption of novel technologies (New drug delivery system). However, there is a large market for reasonably priced medical medicines in India and China's fiercely competitive mass marketplaces. Before embarking on new growth initiatives, companies in the superdisintegrants market must take these trends into account. Several large excipient manufacturers are planning capacity expansions at existing facilities in growing markets such as China and India or are establishing new production sites in emerging markets such as China and India.
KEY MARKET PLAYERS:
A few of the notable companies leading the Asia Pacific Superdisintegrants Market covered in this report are Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co., and Huber Corporation.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Natural Superdisintegrants
5.1.3 Synthetic Superdisintegrants
5.1.3.1 Modified Starch
5.1.3.2 Crospovidone
5.1.3.3 Modified Cellulose
5.1.3.4 Ion Exchange Resins
5.1.3.5 Calcium Silicates
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Product Type
5.1.6 Market Attractiveness Analysis, By Product Type
5.1.7 Market Share Analysis, By Product Type
5.2 Application
5.2.1 Introduction
5.2.2 Capsules
5.2.3 Tablets
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
5.3 Therapeutic Area
5.3.1 Introduction
5.3.2 Gastrointestinal diseases
5.3.3 Neurological diseases
5.3.4 Oncology
5.3.5 Infectious Diseases
5.3.6 Cardiovascular Diseases
5.3.7 Haematological diseases
5.3.8 Inflammatory Diseases
5.3.9 Y-o-Y Growth Analysis, By Therapeutic Area
5.3.10 Market Attractiveness Analysis, By Therapeutic Area
5.3.11 Market Share Analysis, By Therapeutic Area
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By Application
6.1.3.4 By Therapeutic Area
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By Application
6.1.4.4 By Therapeutic Area
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By Application
6.1.5.4 By Therapeutic Area
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Ashland
8.1.1 Overview
8.1.2 Product Type Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 BASF SE
8.3 FMC Corporation
8.4 JRS Pharma
8.5 DFE Pharma
8.6 Roquette
8.7 The Dow Chemical Company
8.8 Asahi Kasei Corporation
8.9 Nippon Soda Co.
8.10 Huber Corporation
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
